Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 65, Issue 10, 2013, Pages 2661-2671

  Szepietowski, Jacek C ^a   Nilganuwong, Surasak ^b   Wozniacka, Anna ^c   Kuhn, Annegret ^d   Nyberg, Filippa ^e   Van Vollenhoven, Ronald F ^f   Bengtsson, Anders A ^g   Reich, Adam ^a   De Vries, Dick E ^h   Van Hartingsveldt, Bart ^h   Robinson Jr , Donald W ⁱ   Gordon, Robert ^j   Hsu, Benjamin ^j  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e DANDERYD HOSPITAL   (Sweden)

^f KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY   (Sweden)

^h Janssen Biologics   (Netherlands)

ⁱ Janssen Global Services   (United States)

^j JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 6 RECEPTOR; PLACEBO; SERUM AMYLOID A; SIRUKUMAB; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ABDOMINAL PAIN; ADULT; AGED; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOGENICITY; LEUKOCYTE COUNT; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SKIN LUPUS ERYTHEMATOSUS; SKIN ULCER; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WOUND INFECTION;

ADULT; AGED; ANTIBODIES, MONOCLONAL; C-REACTIVE PROTEIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; INTERNATIONAL COOPERATION; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SERUM AMYLOID A PROTEIN; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84885153193     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38091     Document Type: Article

References (35)

1. Kitani A, Hara M, Hirose T, Harigai M, Suzuki K, Kawakami M, et al. Autostimulatory effects of IL-6 on excessive B cell differentiation in patients with systemic lupus erythematosus: analysis of IL-6 production and IL-6R expression. Clin Exp Immunol 1992; 88: 75-83.
2. Monneaux F, Muller S,. Peptide-based immunotherapy of systemic lupus erythematosus. Autoimmun Rev 2004; 3: 16-24.
3. Urbanski A, Schwarz T, Neuner P, Krutmann J, Kirnbauer R, Kock A, et al. Ultraviolet light induces increased circulating interleukin-6 in humans. J Invest Dermatol 1990; 94: 808-11.
4. De Vos S, Brach M, Budnik A, Grewe M, Herrmann F, Krutmann J,. Post-transcriptional regulation of interleukin-6 gene expression in human keratinocytes by ultraviolet B radiation. J Invest Dermatol 1994; 103: 92-6.
5. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR,. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991; 147: 117-23.
6. Wallace DJ, Linker-Israeli M, Hyun S, Klinenberg JR, Stecher V,. The effect of hydroxychloroquine therapy on serum levels of immunoregulatory molecules in patients with systemic lupus erythematosus [letter]. J Rheumatol 1994; 21: 375-6.
7. Durosaro O, Davis MD, Reed KB, Rohlinger AL,. Incidence of cutaneous lupus erythematosus, 1965-2005: a population-based study. Arch Dermatol 2009; 145: 249-53.
8. Tebbe B, Orfanos CE,. Epidemiology and socioeconomic impact of skin disease in lupus erythematosus. Lupus 1997; 6: 96-104.
9. Kuhn A, Ruland V, Bonsmann G,. Cutaneous lupus erythematosus: update of therapeutic options: part I. J Am Acad Dermatol 2011; 65: e179-93.
10. Walling HW, Sontheimer RD,. Cutaneous lupus erythematosus: issues in diagnosis and treatment. Am J Clin Dermatol 2009; 10: 365-81.
11. Kobak S, Deveci H,. Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. Int J Rheum Dis 2010; 13: e11-5.
12. Francis L, Perl A,. Pharmacotherapy of systemic lupus erythematosus [review]. Expert Opin Pharmacother 2009; 10: 1481-94.
13. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2550-7.
14. Xu Z, Bouman-Thio E, Comisar C, Frederick B, Van Hartingsveldt B, Marini JC, et al. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study. Br J Clin Pharmacol 2011; 72: 270-81.
15. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
16. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
17. Petri M, Kim MY, Kalunian KC, Grossman J, Hahn BH, Sammaritano LR, et al, for the OC-SELENA Trial. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med 2005; 353: 2550-8.
18. Albrecht J, Taylor L, Berlin JA, Dulay S, Ang G, Fakharzadeh S, et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005; 125: 889-94.
19. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447-58.
20. Isenberg DA, Gordon C, for the British Isles Lupus Assessment Group (BILAG). From BILAG to BLIPS-disease activity assessment in lupus past, present and future. Lupus 2000; 9: 651-4.
21. Petri M, Buyon J, Kim M,. Classification and definition of major flares in SLE clinical trials. Lupus 1999; 8: 685-91.
22. Robinson D Jr, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldman R, et al. Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. Arthritis Care Res (Hoboken) 2010; 62: 266-73.
23. Stamm TA, Bauernfeind B, Coenen M, Feierl E, Mathis M, Stucki G, et al. Concepts important to persons with systemic lupus erythematosus and their coverage by standard measures of disease activity and health status. Arthritis Rheum 2007; 57: 1287-95.
24. Klein R, Moghadam-Kia S, Taylor L, Coley C, Okawa J, LoMonico J, et al. Quality of life in cutaneous lupus erythematosus. J Am Acad Dermatol 2011; 64: 849-58.
25. McElhone K, Abbott J, Gray J, Williams A, Teh LS,. Patient perspective of systemic lupus erythematosus in relation to health-related quality of life concepts: a qualitative study. Lupus 2010; 19: 1640-7.
26. Touma Z, Gladman DD, Ibanez D, Urowitz MB,. Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus? J Rheumatol 2011; 38: 1898-905.
27. Finlay AY, Khan GK,. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-6.
28. Ware JE Jr, Sherbourne CD,. The MOS 36-item Short-Form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473-83.
29. Maeda K, Malykhin A, Teague-Weber BN, Sun XH, Farris AD, Coggeshall KM,. Interleukin-6 aborts lymphopoiesis and elevates production of myeloid cells in systemic lupus erythematosus-prone B6.Sle1.Yaa animals. Blood 2009; 113: 4534-40.
30. Illei GG, Shirota Y, Yarboro CH, Daruwalla J, Tackey E, Takada K, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010; 62: 542-52.
31. Kawashiri SY, Kawakami A, Yamasaki S, Imazato T, Iwamoto N, Fujikawa K, et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol Int 2011; 31: 451-6.
32. Liu CC, Kao AH, Hawkins DM, Manzi S, Sattar A, Wilson N, et al. Lymphocyte-bound complement activation products as biomarkers for diagnosis of systemic lupus erythematosus. Clin Transl Sci 2009; 2: 300-8.
33. Navarra SV, Guzman RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, et al, for the BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377: 721-31.
34. Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009; 61: 1168-78.
35. Colangelo KJ, Pope JE, Peschken C,. The minimally important difference for patient reported outcomes in systemic lupus erythematosus including the HAQ-DI, pain, fatigue, and SF-36. J Rheumatol 2009; 36: 2231-7.